Medical Care
Global Human Oocyte Cryopreservation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jul 24, 25
- ID: 403850
- Pages: 159
- Figures: 154
- Views: 20
In 2024, the global market size of Human Oocyte Cryopreservation was estimated to be worth US$ 91 million and is forecast to reach approximately US$ 239 million by 2031 with a CAGR of 15.0% during the forecast period 2025-2031.
Human oocyte cryopreservation (egg freezing) is a procedure to preserve female eggs (oocytes). The eggs are extracted, frozen and stored. The purpose of the procedure is to give women the option of thawing, fertilizing and transplanting the eggs into the uterus as embryos to promote future pregnancy.
Oocyte cryopreservation refers to the technology of cooling human oocytes and storing them in liquid nitrogen (generally stored in liquid nitrogen at -196°C), resuscitating (thawing) them when needed, and ensuring that the oocytes are alive and functioning normally. It is a derivative technology of assisted reproductive technology, mainly used to treat infertility and preserve female fertility.
The driving factors of the oocyte cryopreservation market mainly include the following aspects:
Technological progress
The continuous improvement and maturity of oocyte cryopreservation technology has improved the recovery rate and survival rate of frozen oocytes, thereby increasing the clinical application prospects of this technology and driving the development of the market.
Changes in fertility concepts
The changes in modern women's fertility concepts and the intensification of the trend of late marriage and late childbearing have led more and more women to choose oocyte cryopreservation technology to maintain fertility and provide guarantees for future fertility plans.
Growth in medical demand
With the improvement of medical standards and people's attention to reproductive health, more and more medical institutions and patients have begun to pay attention to oocyte cryopreservation technology, which has promoted the rapid development of the market.
Policy support
The support policies of some countries and regions for assisted reproductive technology, as well as the improvement of relevant laws and regulations, have provided a good policy environment for the development of oocyte cryopreservation technology.
Unlike sperm, oocytes are larger and contain a lot of water, which makes it easier to form ice crystals that may damage the eggs during the freezing process. In addition, egg extraction is not easy and the number is scarce, so the selection of protective agents during the freezing process is also more demanding. These factors have made egg freezing one of the difficulties in freezing technology.
However, with the continuous advancement of technology, the success rate of oocyte cryopreservation has been significantly improved. International clinical trials have proven that frozen eggs can be stored for at least ten years, and they still have the ability to conceive after thawing, can form healthy embryos, and can normally conceive babies. This has led more and more women to choose to preserve their future reproductive ability through oocyte cryopreservation technology, that is, to buy a "fertility insurance".
In general, oocyte cryopreservation technology provides an effective option for women who want to preserve their fertility, and also provides new possibilities for the development of assisted reproductive technology.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Oocyte Cryopreservation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Oocyte Cryopreservation.
The Human Oocyte Cryopreservation market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Oocyte Cryopreservation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Oocyte Cryopreservation companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Anova Fertility
CCRM IVF
Chill
CREATE Fertility
Extend Fertility
HRC Fertility
IVF Australia
Kindbody
London Women’s Clinic
Manchester Fertility
Mayo Clinic
Melbourne IVF
Monash IVF
Pacific Fertility Center-Los Angeles (PFCLA)
PIVET
Prelude Fertility
Segment by Type
Slow-cooling Method
Flash-freezing Process (Vitrification)
Segment by Application
25-30 Year Old Female
30-35 Year Old Female
35-40 Year Old Female
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Human Oocyte Cryopreservation in global and regional level.
Chapter 3: Detailed analysis of Human Oocyte Cryopreservation company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Oocyte Cryopreservation revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Human oocyte cryopreservation (egg freezing) is a procedure to preserve female eggs (oocytes). The eggs are extracted, frozen and stored. The purpose of the procedure is to give women the option of thawing, fertilizing and transplanting the eggs into the uterus as embryos to promote future pregnancy.
Oocyte cryopreservation refers to the technology of cooling human oocytes and storing them in liquid nitrogen (generally stored in liquid nitrogen at -196°C), resuscitating (thawing) them when needed, and ensuring that the oocytes are alive and functioning normally. It is a derivative technology of assisted reproductive technology, mainly used to treat infertility and preserve female fertility.
The driving factors of the oocyte cryopreservation market mainly include the following aspects:
Technological progress
The continuous improvement and maturity of oocyte cryopreservation technology has improved the recovery rate and survival rate of frozen oocytes, thereby increasing the clinical application prospects of this technology and driving the development of the market.
Changes in fertility concepts
The changes in modern women's fertility concepts and the intensification of the trend of late marriage and late childbearing have led more and more women to choose oocyte cryopreservation technology to maintain fertility and provide guarantees for future fertility plans.
Growth in medical demand
With the improvement of medical standards and people's attention to reproductive health, more and more medical institutions and patients have begun to pay attention to oocyte cryopreservation technology, which has promoted the rapid development of the market.
Policy support
The support policies of some countries and regions for assisted reproductive technology, as well as the improvement of relevant laws and regulations, have provided a good policy environment for the development of oocyte cryopreservation technology.
Unlike sperm, oocytes are larger and contain a lot of water, which makes it easier to form ice crystals that may damage the eggs during the freezing process. In addition, egg extraction is not easy and the number is scarce, so the selection of protective agents during the freezing process is also more demanding. These factors have made egg freezing one of the difficulties in freezing technology.
However, with the continuous advancement of technology, the success rate of oocyte cryopreservation has been significantly improved. International clinical trials have proven that frozen eggs can be stored for at least ten years, and they still have the ability to conceive after thawing, can form healthy embryos, and can normally conceive babies. This has led more and more women to choose to preserve their future reproductive ability through oocyte cryopreservation technology, that is, to buy a "fertility insurance".
In general, oocyte cryopreservation technology provides an effective option for women who want to preserve their fertility, and also provides new possibilities for the development of assisted reproductive technology.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Oocyte Cryopreservation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Oocyte Cryopreservation.
The Human Oocyte Cryopreservation market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Oocyte Cryopreservation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Oocyte Cryopreservation companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Anova Fertility
CCRM IVF
Chill
CREATE Fertility
Extend Fertility
HRC Fertility
IVF Australia
Kindbody
London Women’s Clinic
Manchester Fertility
Mayo Clinic
Melbourne IVF
Monash IVF
Pacific Fertility Center-Los Angeles (PFCLA)
PIVET
Prelude Fertility
Segment by Type
Slow-cooling Method
Flash-freezing Process (Vitrification)
Segment by Application
25-30 Year Old Female
30-35 Year Old Female
35-40 Year Old Female
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Human Oocyte Cryopreservation in global and regional level.
Chapter 3: Detailed analysis of Human Oocyte Cryopreservation company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Oocyte Cryopreservation revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Human Oocyte Cryopreservation Product Introduction
1.2 Market by Type
1.2.1 Global Human Oocyte Cryopreservation Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Slow-cooling Method
1.2.3 Flash-freezing Process (Vitrification)
1.3 Market by Application
1.3.1 Global Human Oocyte Cryopreservation Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 25-30 Year Old Female
1.3.3 30-35 Year Old Female
1.3.4 35-40 Year Old Female
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Oocyte Cryopreservation Market Size Estimates and Forecasts
2.2 Human Oocyte Cryopreservation Market Size by Region: 2024 Versus 2031
2.2.1 Global Human Oocyte Cryopreservation Revenue by Region: 2020-2025
2.2.2 Global Human Oocyte Cryopreservation Revenue Forecast by Region (2026-2031)
2.2.3 Global Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Human Oocyte Cryopreservation Revenue by Type (2020-2031)
3.1.2 Global Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Human Oocyte Cryopreservation Revenue by Application (2020-2031)
3.2.2 Global Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Slow-cooling Method of Human Oocyte Cryopreservation Revenue Market Share by Application
3.3.2 Flash-freezing Process (Vitrification) of Human Oocyte Cryopreservation Revenue Market Share by Application
4 Global Human Oocyte Cryopreservation by Company
4.1 Global Human Oocyte Cryopreservation Revenue by Company (2020-2025)
4.2 Global Human Oocyte Cryopreservation Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Human Oocyte Cryopreservation Companies around the World: Ranking by Revenue
4.3.2 Global Human Oocyte Cryopreservation Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Human Oocyte Cryopreservation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Human Oocyte Cryopreservation Companies Headquarters & Product Type
4.4.1 Global Human Oocyte Cryopreservation Companies Headquarters
4.4.2 Date of International Companies Enter into Human Oocyte Cryopreservation Market
4.4.3 Global Human Oocyte Cryopreservation Companies Product & Service
4.4.4 Slow-cooling Method Revenue Market Share of Human Oocyte Cryopreservation by Company
4.4.5 Flash-freezing Process (Vitrification) Revenue Market Share of Human Oocyte Cryopreservation by Company
4.5 Global Human Oocyte Cryopreservation Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Anova Fertility
5.1.1 Anova Fertility Corporation Information
5.1.2 Anova Fertility Description, Business Overview
5.1.3 Anova Fertility Human Oocyte Cryopreservation Products Offered
5.1.4 Anova Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.1.5 Anova Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.1.6 Anova Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.1.7 Anova Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.1.8 Anova Fertility Recent Developments
5.2 CCRM IVF
5.2.1 CCRM IVF Corporation Information
5.2.2 CCRM IVF Description, Business Overview
5.2.3 CCRM IVF Human Oocyte Cryopreservation Products Offered
5.2.4 CCRM IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.2.5 CCRM IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.2.6 CCRM IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.2.7 CCRM IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.2.8 CCRM IVF Recent Developments
5.3 Chill
5.3.1 Chill Corporation Information
5.3.2 Chill Description, Business Overview
5.3.3 Chill Human Oocyte Cryopreservation Products Offered
5.3.4 Chill Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.3.5 Chill Human Oocyte Cryopreservation Revenue by Product in 2024
5.3.6 Chill Human Oocyte Cryopreservation Revenue by Application in 2024
5.3.7 Chill Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.3.8 Chill Recent Developments
5.4 CREATE Fertility
5.4.1 CREATE Fertility Corporation Information
5.4.2 CREATE Fertility Description, Business Overview
5.4.3 CREATE Fertility Human Oocyte Cryopreservation Products Offered
5.4.4 CREATE Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.4.5 CREATE Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.4.6 CREATE Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.4.7 CREATE Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.4.8 CREATE Fertility Recent Developments
5.5 Extend Fertility
5.5.1 Extend Fertility Corporation Information
5.5.2 Extend Fertility Description, Business Overview
5.5.3 Extend Fertility Human Oocyte Cryopreservation Products Offered
5.5.4 Extend Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.5.5 Extend Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.5.6 Extend Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.5.7 Extend Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.5.8 Extend Fertility Recent Developments
5.6 HRC Fertility
5.6.1 HRC Fertility Corporation Information
5.6.2 HRC Fertility Description, Business Overview
5.6.3 HRC Fertility Human Oocyte Cryopreservation Products Offered
5.6.4 HRC Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.6.5 HRC Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.6.6 HRC Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.6.7 HRC Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.6.8 HRC Fertility Recent Developments
5.7 IVF Australia
5.7.1 IVF Australia Corporation Information
5.7.2 IVF Australia Description, Business Overview
5.7.3 IVF Australia Human Oocyte Cryopreservation Products Offered
5.7.4 IVF Australia Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.7.5 IVF Australia Human Oocyte Cryopreservation Revenue by Product in 2024
5.7.6 IVF Australia Human Oocyte Cryopreservation Revenue by Application in 2024
5.7.7 IVF Australia Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.7.8 IVF Australia Recent Developments
5.8 Kindbody
5.8.1 Kindbody Corporation Information
5.8.2 Kindbody Description, Business Overview
5.8.3 Kindbody Human Oocyte Cryopreservation Products Offered
5.8.4 Kindbody Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.8.5 Kindbody Human Oocyte Cryopreservation Revenue by Product in 2024
5.8.6 Kindbody Human Oocyte Cryopreservation Revenue by Application in 2024
5.8.7 Kindbody Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.8.8 Kindbody Recent Developments
5.9 London Women’s Clinic
5.9.1 London Women’s Clinic Corporation Information
5.9.2 London Women’s Clinic Description, Business Overview
5.9.3 London Women’s Clinic Human Oocyte Cryopreservation Products Offered
5.9.4 London Women’s Clinic Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.9.5 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Product in 2024
5.9.6 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Application in 2024
5.9.7 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.9.8 London Women’s Clinic Recent Developments
5.10 Manchester Fertility
5.10.1 Manchester Fertility Corporation Information
5.10.2 Manchester Fertility Description, Business Overview
5.10.3 Manchester Fertility Human Oocyte Cryopreservation Products Offered
5.10.4 Manchester Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.10.5 Manchester Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.10.6 Manchester Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.10.7 Manchester Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.10.8 Manchester Fertility Recent Developments
5.11 Mayo Clinic
5.11.1 Mayo Clinic Corporation Information
5.11.2 Mayo Clinic Description, Business Overview
5.11.3 Mayo Clinic Human Oocyte Cryopreservation Products Offered
5.11.4 Mayo Clinic Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.11.5 Mayo Clinic Human Oocyte Cryopreservation Revenue by Product in 2024
5.11.6 Mayo Clinic Human Oocyte Cryopreservation Revenue by Application in 2024
5.11.7 Mayo Clinic Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.11.8 Mayo Clinic Recent Developments
5.12 Melbourne IVF
5.12.1 Melbourne IVF Corporation Information
5.12.2 Melbourne IVF Description, Business Overview
5.12.3 Melbourne IVF Human Oocyte Cryopreservation Products Offered
5.12.4 Melbourne IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.12.5 Melbourne IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.12.6 Melbourne IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.12.7 Melbourne IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.12.8 Melbourne IVF Recent Developments
5.13 Monash IVF
5.13.1 Monash IVF Corporation Information
5.13.2 Monash IVF Description, Business Overview
5.13.3 Monash IVF Human Oocyte Cryopreservation Products Offered
5.13.4 Monash IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.13.5 Monash IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.13.6 Monash IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.13.7 Monash IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.13.8 Monash IVF Recent Developments
5.14 Pacific Fertility Center-Los Angeles (PFCLA)
5.14.1 Pacific Fertility Center-Los Angeles (PFCLA) Corporation Information
5.14.2 Pacific Fertility Center-Los Angeles (PFCLA) Description, Business Overview
5.14.3 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Products Offered
5.14.4 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.14.5 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Product in 2024
5.14.6 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Application in 2024
5.14.7 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.14.8 Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
5.15 PIVET
5.15.1 PIVET Corporation Information
5.15.2 PIVET Description, Business Overview
5.15.3 PIVET Human Oocyte Cryopreservation Products Offered
5.15.4 PIVET Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.15.5 PIVET Human Oocyte Cryopreservation Revenue by Product in 2024
5.15.6 PIVET Human Oocyte Cryopreservation Revenue by Application in 2024
5.15.7 PIVET Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.15.8 PIVET Recent Developments
5.16 Prelude Fertility
5.16.1 Prelude Fertility Corporation Information
5.16.2 Prelude Fertility Description, Business Overview
5.16.3 Prelude Fertility Human Oocyte Cryopreservation Products Offered
5.16.4 Prelude Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.16.5 Prelude Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.16.6 Prelude Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.16.7 Prelude Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.16.8 Prelude Fertility Recent Developments
6 North America
6.1 North America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
6.2 North America Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
6.3 North America Human Oocyte Cryopreservation Revenue by Type (2020-2025)
6.4 North America Human Oocyte Cryopreservation Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Human Oocyte Cryopreservation Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Human Oocyte Cryopreservation Revenue by Type (2020-2025)
7.4 Asia-Pacific Human Oocyte Cryopreservation Revenue by Application (2020-2025)
8 Europe
8.1 Europe Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
8.2 Europe Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
8.3 Europe Human Oocyte Cryopreservation Revenue by Type (2020-2025)
8.4 Europe Human Oocyte Cryopreservation Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
9.2 Latin America Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
9.3 Latin America Human Oocyte Cryopreservation Revenue by Type (2020-2025)
9.4 Latin America Human Oocyte Cryopreservation Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Human Oocyte Cryopreservation Revenue by Type (2020-2025)
10.4 Middle East and Africa Human Oocyte Cryopreservation Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Human Oocyte Cryopreservation Supply Chain Analysis
11.2 Human Oocyte Cryopreservation Key Raw Materials and Upstream Suppliers
11.3 Human Oocyte Cryopreservation Clients Analysis
11.4 Human Oocyte Cryopreservation Sales Channel and Sales Model Analysis
11.4.1 Human Oocyte Cryopreservation Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Human Oocyte Cryopreservation Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Human Oocyte Cryopreservation Distributors
12 Human Oocyte Cryopreservation Market Dynamics
12.1 Human Oocyte Cryopreservation Industry Trends
12.2 Human Oocyte Cryopreservation Market Drivers
12.3 Human Oocyte Cryopreservation Market Challenges
12.4 Human Oocyte Cryopreservation Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Human Oocyte Cryopreservation Product Introduction
1.2 Market by Type
1.2.1 Global Human Oocyte Cryopreservation Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Slow-cooling Method
1.2.3 Flash-freezing Process (Vitrification)
1.3 Market by Application
1.3.1 Global Human Oocyte Cryopreservation Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 25-30 Year Old Female
1.3.3 30-35 Year Old Female
1.3.4 35-40 Year Old Female
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Oocyte Cryopreservation Market Size Estimates and Forecasts
2.2 Human Oocyte Cryopreservation Market Size by Region: 2024 Versus 2031
2.2.1 Global Human Oocyte Cryopreservation Revenue by Region: 2020-2025
2.2.2 Global Human Oocyte Cryopreservation Revenue Forecast by Region (2026-2031)
2.2.3 Global Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Human Oocyte Cryopreservation Revenue by Type (2020-2031)
3.1.2 Global Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Human Oocyte Cryopreservation Revenue by Application (2020-2031)
3.2.2 Global Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Slow-cooling Method of Human Oocyte Cryopreservation Revenue Market Share by Application
3.3.2 Flash-freezing Process (Vitrification) of Human Oocyte Cryopreservation Revenue Market Share by Application
4 Global Human Oocyte Cryopreservation by Company
4.1 Global Human Oocyte Cryopreservation Revenue by Company (2020-2025)
4.2 Global Human Oocyte Cryopreservation Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Human Oocyte Cryopreservation Companies around the World: Ranking by Revenue
4.3.2 Global Human Oocyte Cryopreservation Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Human Oocyte Cryopreservation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Human Oocyte Cryopreservation Companies Headquarters & Product Type
4.4.1 Global Human Oocyte Cryopreservation Companies Headquarters
4.4.2 Date of International Companies Enter into Human Oocyte Cryopreservation Market
4.4.3 Global Human Oocyte Cryopreservation Companies Product & Service
4.4.4 Slow-cooling Method Revenue Market Share of Human Oocyte Cryopreservation by Company
4.4.5 Flash-freezing Process (Vitrification) Revenue Market Share of Human Oocyte Cryopreservation by Company
4.5 Global Human Oocyte Cryopreservation Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Anova Fertility
5.1.1 Anova Fertility Corporation Information
5.1.2 Anova Fertility Description, Business Overview
5.1.3 Anova Fertility Human Oocyte Cryopreservation Products Offered
5.1.4 Anova Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.1.5 Anova Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.1.6 Anova Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.1.7 Anova Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.1.8 Anova Fertility Recent Developments
5.2 CCRM IVF
5.2.1 CCRM IVF Corporation Information
5.2.2 CCRM IVF Description, Business Overview
5.2.3 CCRM IVF Human Oocyte Cryopreservation Products Offered
5.2.4 CCRM IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.2.5 CCRM IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.2.6 CCRM IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.2.7 CCRM IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.2.8 CCRM IVF Recent Developments
5.3 Chill
5.3.1 Chill Corporation Information
5.3.2 Chill Description, Business Overview
5.3.3 Chill Human Oocyte Cryopreservation Products Offered
5.3.4 Chill Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.3.5 Chill Human Oocyte Cryopreservation Revenue by Product in 2024
5.3.6 Chill Human Oocyte Cryopreservation Revenue by Application in 2024
5.3.7 Chill Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.3.8 Chill Recent Developments
5.4 CREATE Fertility
5.4.1 CREATE Fertility Corporation Information
5.4.2 CREATE Fertility Description, Business Overview
5.4.3 CREATE Fertility Human Oocyte Cryopreservation Products Offered
5.4.4 CREATE Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.4.5 CREATE Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.4.6 CREATE Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.4.7 CREATE Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.4.8 CREATE Fertility Recent Developments
5.5 Extend Fertility
5.5.1 Extend Fertility Corporation Information
5.5.2 Extend Fertility Description, Business Overview
5.5.3 Extend Fertility Human Oocyte Cryopreservation Products Offered
5.5.4 Extend Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.5.5 Extend Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.5.6 Extend Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.5.7 Extend Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.5.8 Extend Fertility Recent Developments
5.6 HRC Fertility
5.6.1 HRC Fertility Corporation Information
5.6.2 HRC Fertility Description, Business Overview
5.6.3 HRC Fertility Human Oocyte Cryopreservation Products Offered
5.6.4 HRC Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.6.5 HRC Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.6.6 HRC Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.6.7 HRC Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.6.8 HRC Fertility Recent Developments
5.7 IVF Australia
5.7.1 IVF Australia Corporation Information
5.7.2 IVF Australia Description, Business Overview
5.7.3 IVF Australia Human Oocyte Cryopreservation Products Offered
5.7.4 IVF Australia Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.7.5 IVF Australia Human Oocyte Cryopreservation Revenue by Product in 2024
5.7.6 IVF Australia Human Oocyte Cryopreservation Revenue by Application in 2024
5.7.7 IVF Australia Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.7.8 IVF Australia Recent Developments
5.8 Kindbody
5.8.1 Kindbody Corporation Information
5.8.2 Kindbody Description, Business Overview
5.8.3 Kindbody Human Oocyte Cryopreservation Products Offered
5.8.4 Kindbody Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.8.5 Kindbody Human Oocyte Cryopreservation Revenue by Product in 2024
5.8.6 Kindbody Human Oocyte Cryopreservation Revenue by Application in 2024
5.8.7 Kindbody Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.8.8 Kindbody Recent Developments
5.9 London Women’s Clinic
5.9.1 London Women’s Clinic Corporation Information
5.9.2 London Women’s Clinic Description, Business Overview
5.9.3 London Women’s Clinic Human Oocyte Cryopreservation Products Offered
5.9.4 London Women’s Clinic Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.9.5 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Product in 2024
5.9.6 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Application in 2024
5.9.7 London Women’s Clinic Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.9.8 London Women’s Clinic Recent Developments
5.10 Manchester Fertility
5.10.1 Manchester Fertility Corporation Information
5.10.2 Manchester Fertility Description, Business Overview
5.10.3 Manchester Fertility Human Oocyte Cryopreservation Products Offered
5.10.4 Manchester Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.10.5 Manchester Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.10.6 Manchester Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.10.7 Manchester Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.10.8 Manchester Fertility Recent Developments
5.11 Mayo Clinic
5.11.1 Mayo Clinic Corporation Information
5.11.2 Mayo Clinic Description, Business Overview
5.11.3 Mayo Clinic Human Oocyte Cryopreservation Products Offered
5.11.4 Mayo Clinic Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.11.5 Mayo Clinic Human Oocyte Cryopreservation Revenue by Product in 2024
5.11.6 Mayo Clinic Human Oocyte Cryopreservation Revenue by Application in 2024
5.11.7 Mayo Clinic Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.11.8 Mayo Clinic Recent Developments
5.12 Melbourne IVF
5.12.1 Melbourne IVF Corporation Information
5.12.2 Melbourne IVF Description, Business Overview
5.12.3 Melbourne IVF Human Oocyte Cryopreservation Products Offered
5.12.4 Melbourne IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.12.5 Melbourne IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.12.6 Melbourne IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.12.7 Melbourne IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.12.8 Melbourne IVF Recent Developments
5.13 Monash IVF
5.13.1 Monash IVF Corporation Information
5.13.2 Monash IVF Description, Business Overview
5.13.3 Monash IVF Human Oocyte Cryopreservation Products Offered
5.13.4 Monash IVF Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.13.5 Monash IVF Human Oocyte Cryopreservation Revenue by Product in 2024
5.13.6 Monash IVF Human Oocyte Cryopreservation Revenue by Application in 2024
5.13.7 Monash IVF Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.13.8 Monash IVF Recent Developments
5.14 Pacific Fertility Center-Los Angeles (PFCLA)
5.14.1 Pacific Fertility Center-Los Angeles (PFCLA) Corporation Information
5.14.2 Pacific Fertility Center-Los Angeles (PFCLA) Description, Business Overview
5.14.3 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Products Offered
5.14.4 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.14.5 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Product in 2024
5.14.6 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Application in 2024
5.14.7 Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.14.8 Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
5.15 PIVET
5.15.1 PIVET Corporation Information
5.15.2 PIVET Description, Business Overview
5.15.3 PIVET Human Oocyte Cryopreservation Products Offered
5.15.4 PIVET Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.15.5 PIVET Human Oocyte Cryopreservation Revenue by Product in 2024
5.15.6 PIVET Human Oocyte Cryopreservation Revenue by Application in 2024
5.15.7 PIVET Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.15.8 PIVET Recent Developments
5.16 Prelude Fertility
5.16.1 Prelude Fertility Corporation Information
5.16.2 Prelude Fertility Description, Business Overview
5.16.3 Prelude Fertility Human Oocyte Cryopreservation Products Offered
5.16.4 Prelude Fertility Human Oocyte Cryopreservation Revenue and Gross Margin (2020-2025)
5.16.5 Prelude Fertility Human Oocyte Cryopreservation Revenue by Product in 2024
5.16.6 Prelude Fertility Human Oocyte Cryopreservation Revenue by Application in 2024
5.16.7 Prelude Fertility Human Oocyte Cryopreservation Revenue by Geographic Area in 2024
5.16.8 Prelude Fertility Recent Developments
6 North America
6.1 North America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
6.2 North America Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
6.3 North America Human Oocyte Cryopreservation Revenue by Type (2020-2025)
6.4 North America Human Oocyte Cryopreservation Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Human Oocyte Cryopreservation Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Human Oocyte Cryopreservation Revenue by Type (2020-2025)
7.4 Asia-Pacific Human Oocyte Cryopreservation Revenue by Application (2020-2025)
8 Europe
8.1 Europe Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
8.2 Europe Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
8.3 Europe Human Oocyte Cryopreservation Revenue by Type (2020-2025)
8.4 Europe Human Oocyte Cryopreservation Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
9.2 Latin America Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
9.3 Latin America Human Oocyte Cryopreservation Revenue by Type (2020-2025)
9.4 Latin America Human Oocyte Cryopreservation Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Human Oocyte Cryopreservation Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Human Oocyte Cryopreservation Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Human Oocyte Cryopreservation Revenue by Type (2020-2025)
10.4 Middle East and Africa Human Oocyte Cryopreservation Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Human Oocyte Cryopreservation Supply Chain Analysis
11.2 Human Oocyte Cryopreservation Key Raw Materials and Upstream Suppliers
11.3 Human Oocyte Cryopreservation Clients Analysis
11.4 Human Oocyte Cryopreservation Sales Channel and Sales Model Analysis
11.4.1 Human Oocyte Cryopreservation Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Human Oocyte Cryopreservation Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Human Oocyte Cryopreservation Distributors
12 Human Oocyte Cryopreservation Market Dynamics
12.1 Human Oocyte Cryopreservation Industry Trends
12.2 Human Oocyte Cryopreservation Market Drivers
12.3 Human Oocyte Cryopreservation Market Challenges
12.4 Human Oocyte Cryopreservation Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Human Oocyte Cryopreservation Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Human Oocyte Cryopreservation Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Human Oocyte Cryopreservation Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Human Oocyte Cryopreservation Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Oocyte Cryopreservation Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Human Oocyte Cryopreservation Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Human Oocyte Cryopreservation Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Human Oocyte Cryopreservation Revenue by Company (2020-2025) & (US$ Million)
Table 11. Human Oocyte Cryopreservation Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Human Oocyte Cryopreservation Players by Revenue (US$ Million) in 2024
Table 13. Global Human Oocyte Cryopreservation Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Human Oocyte Cryopreservation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Oocyte Cryopreservation as of 2024)
Table 15. Global Human Oocyte Cryopreservation Companies Headquarters
Table 16. Date of International Companies Enter into Human Oocyte Cryopreservation Market
Table 17. Global Human Oocyte Cryopreservation Companies Product & Service
Table 18. Global Human Oocyte Cryopreservation Mergers & Acquisitions, Expansion Plans
Table 19. Anova Fertility Corporation Information
Table 20. Anova Fertility Description and Business Overview
Table 21. Anova Fertility Human Oocyte Cryopreservation Product
Table 22. Anova Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 24. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 25. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 26. Anova Fertility Recent Developments
Table 27. CCRM IVF Corporation Information
Table 28. CCRM IVF Description and Business Overview
Table 29. CCRM IVF Human Oocyte Cryopreservation Product
Table 30. CCRM IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 32. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 33. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 34. CCRM IVF Recent Developments
Table 35. Chill Corporation Information
Table 36. Chill Description and Business Overview
Table 37. Chill Human Oocyte Cryopreservation Product
Table 38. Chill Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Chill Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 40. Chill Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 41. Chill Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 42. Chill Recent Developments
Table 43. CREATE Fertility Corporation Information
Table 44. CREATE Fertility Description and Business Overview
Table 45. CREATE Fertility Human Oocyte Cryopreservation Product
Table 46. CREATE Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 48. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 49. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 50. CREATE Fertility Recent Developments
Table 51. Extend Fertility Corporation Information
Table 52. Extend Fertility Description and Business Overview
Table 53. Extend Fertility Human Oocyte Cryopreservation Product
Table 54. Extend Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 56. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 57. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 58. Extend Fertility Recent Developments
Table 59. HRC Fertility Corporation Information
Table 60. HRC Fertility Description and Business Overview
Table 61. HRC Fertility Human Oocyte Cryopreservation Product
Table 62. HRC Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 64. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 65. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 66. HRC Fertility Recent Developments
Table 67. IVF Australia Corporation Information
Table 68. IVF Australia Description and Business Overview
Table 69. IVF Australia Human Oocyte Cryopreservation Product
Table 70. IVF Australia Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 72. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 73. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 74. IVF Australia Recent Developments
Table 75. Kindbody Corporation Information
Table 76. Kindbody Description and Business Overview
Table 77. Kindbody Human Oocyte Cryopreservation Product
Table 78. Kindbody Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 80. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 81. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 82. Kindbody Recent Developments
Table 83. London Women’s Clinic Corporation Information
Table 84. London Women’s Clinic Description and Business Overview
Table 85. London Women’s Clinic Human Oocyte Cryopreservation Product
Table 86. London Women’s Clinic Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 88. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 89. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 90. London Women’s Clinic Recent Developments
Table 91. Manchester Fertility Corporation Information
Table 92. Manchester Fertility Description and Business Overview
Table 93. Manchester Fertility Human Oocyte Cryopreservation Product
Table 94. Manchester Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 96. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 97. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 98. Manchester Fertility Recent Developments
Table 99. Mayo Clinic Corporation Information
Table 100. Mayo Clinic Description and Business Overview
Table 101. Mayo Clinic Human Oocyte Cryopreservation Product
Table 102. Mayo Clinic Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 104. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 105. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 106. Mayo Clinic Recent Developments
Table 107. Melbourne IVF Corporation Information
Table 108. Melbourne IVF Description and Business Overview
Table 109. Melbourne IVF Human Oocyte Cryopreservation Product
Table 110. Melbourne IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 112. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 113. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 114. Melbourne IVF Recent Developments
Table 115. Monash IVF Corporation Information
Table 116. Monash IVF Description and Business Overview
Table 117. Monash IVF Human Oocyte Cryopreservation Product
Table 118. Monash IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 120. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 121. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 122. Monash IVF Recent Developments
Table 123. Pacific Fertility Center-Los Angeles (PFCLA) Corporation Information
Table 124. Pacific Fertility Center-Los Angeles (PFCLA) Description and Business Overview
Table 125. Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Product
Table 126. Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 128. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 129. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 130. Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
Table 131. PIVET Corporation Information
Table 132. PIVET Description and Business Overview
Table 133. PIVET Human Oocyte Cryopreservation Product
Table 134. PIVET Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 136. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 137. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 138. PIVET Recent Developments
Table 139. Prelude Fertility Corporation Information
Table 140. Prelude Fertility Description and Business Overview
Table 141. Prelude Fertility Human Oocyte Cryopreservation Product
Table 142. Prelude Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 144. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 145. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 146. Prelude Fertility Recent Developments
Table 147. North America Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 148. North America Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 149. North America Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 150. North America Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 151. Asia-Pacific Human Oocyte Cryopreservation Revenue by Region (2020-2025) & (US$ Million)
Table 152. Asia-Pacific Human Oocyte Cryopreservation Revenue by Region (2026-2031) & (US$ Million)
Table 153. Asia-Pacific Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 154. Asia-Pacific Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 155. Europe Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 156. Europe Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 157. Europe Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 158. Europe Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 159. Latin America Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 160. Latin America Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 161. Latin America Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 162. Latin America Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 163. Middle East and Africa Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 164. Middle East and Africa Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 165. Middle East and Africa Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 166. Middle East and Africa Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 167. Human Oocyte Cryopreservation Key Raw Materials, Industry Status and Trend
Table 168. Human Oocyte Cryopreservation Key Raw Materials and Upstream Suppliers
Table 169. Human Oocyte Cryopreservation Clients Status and Trend
Table 170. Human Oocyte Cryopreservation Typical Clients
Table 171. Human Oocyte Cryopreservation Distributors
Table 172. Human Oocyte Cryopreservation Market Trends
Table 173. Human Oocyte Cryopreservation Market Drivers
Table 174. Human Oocyte Cryopreservation Market Challenges
Table 175. Human Oocyte Cryopreservation Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Oocyte Cryopreservation Product Picture
Figure 2. Global Human Oocyte Cryopreservation Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Human Oocyte Cryopreservation Revenue Market Share by Type in 2024 & 2031
Figure 4. Slow-cooling Method Product Picture
Figure 5. Flash-freezing Process (Vitrification) Product Picture
Figure 6. Global Human Oocyte Cryopreservation Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Human Oocyte Cryopreservation Revenue Market Share by Application in 2024 & 2031
Figure 8. 25-30 Year Old Female
Figure 9. 30-35 Year Old Female
Figure 10. 35-40 Year Old Female
Figure 11. Others
Figure 12. Human Oocyte Cryopreservation Report Years Considered
Figure 13. Global Human Oocyte Cryopreservation Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Human Oocyte Cryopreservation Market Size (2020-2031) & (US$ Million)
Figure 15. Global Human Oocyte Cryopreservation Market Size Market Share by Region: 2024 Versus 2031
Figure 16. Global Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
Figure 17. Global Human Oocyte Cryopreservation Revenue Market Share Forecast by Type (2020-2031)
Figure 18. Global Human Oocyte Cryopreservation Revenue Market Share Forecast by Application (2020-2031)
Figure 19. Slow-cooling Method of Human Oocyte Cryopreservation Revenue Market Share by Application, 2024 VS 2031
Figure 20. Flash-freezing Process (Vitrification) of Human Oocyte Cryopreservation Revenue Market Share by Application, 2024 VS 2031
Figure 21. Human Oocyte Cryopreservation Revenue Share by Company (2024)
Figure 22. Human Oocyte Cryopreservation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Slow-cooling Method Revenue Proportion by Company in 2024
Figure 24. Flash-freezing Process (Vitrification) Revenue Proportion by Company in 2024
Figure 25. North America Human Oocyte Cryopreservation Revenue 2020-2031 (US$ Million)
Figure 26. North America Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 27. North America Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 28. Asia-Pacific Human Oocyte Cryopreservation Revenue 2020-2031 (US$ Million)
Figure 29. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
Figure 30. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 31. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 32. Europe Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 33. Europe Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 34. Europe Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 35. Europe Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 36. Latin America Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 37. Latin America Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 38. Latin America Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 39. Latin America Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 40. Middle East and Africa Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 42. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 43. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 44. Human Oocyte Cryopreservation Supply Chain (Upstream and Downstream Market)
Figure 45. Global Production Market Share of Human Oocyte Cryopreservation Raw Materials by Region in 2024
Figure 46. Human Oocyte Cryopreservation Distribution Channels
Figure 47. Global Human Oocyte Cryopreservation Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 48. Global Human Oocyte Cryopreservation Percentage 2020-2031: Online Sales VS Offline Sales
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
Table 1. Global Human Oocyte Cryopreservation Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Human Oocyte Cryopreservation Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Human Oocyte Cryopreservation Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Human Oocyte Cryopreservation Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Oocyte Cryopreservation Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Human Oocyte Cryopreservation Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Human Oocyte Cryopreservation Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Human Oocyte Cryopreservation Revenue by Company (2020-2025) & (US$ Million)
Table 11. Human Oocyte Cryopreservation Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Human Oocyte Cryopreservation Players by Revenue (US$ Million) in 2024
Table 13. Global Human Oocyte Cryopreservation Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Human Oocyte Cryopreservation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Oocyte Cryopreservation as of 2024)
Table 15. Global Human Oocyte Cryopreservation Companies Headquarters
Table 16. Date of International Companies Enter into Human Oocyte Cryopreservation Market
Table 17. Global Human Oocyte Cryopreservation Companies Product & Service
Table 18. Global Human Oocyte Cryopreservation Mergers & Acquisitions, Expansion Plans
Table 19. Anova Fertility Corporation Information
Table 20. Anova Fertility Description and Business Overview
Table 21. Anova Fertility Human Oocyte Cryopreservation Product
Table 22. Anova Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 24. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 25. Anova Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 26. Anova Fertility Recent Developments
Table 27. CCRM IVF Corporation Information
Table 28. CCRM IVF Description and Business Overview
Table 29. CCRM IVF Human Oocyte Cryopreservation Product
Table 30. CCRM IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 32. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 33. CCRM IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 34. CCRM IVF Recent Developments
Table 35. Chill Corporation Information
Table 36. Chill Description and Business Overview
Table 37. Chill Human Oocyte Cryopreservation Product
Table 38. Chill Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Chill Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 40. Chill Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 41. Chill Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 42. Chill Recent Developments
Table 43. CREATE Fertility Corporation Information
Table 44. CREATE Fertility Description and Business Overview
Table 45. CREATE Fertility Human Oocyte Cryopreservation Product
Table 46. CREATE Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 48. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 49. CREATE Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 50. CREATE Fertility Recent Developments
Table 51. Extend Fertility Corporation Information
Table 52. Extend Fertility Description and Business Overview
Table 53. Extend Fertility Human Oocyte Cryopreservation Product
Table 54. Extend Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 56. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 57. Extend Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 58. Extend Fertility Recent Developments
Table 59. HRC Fertility Corporation Information
Table 60. HRC Fertility Description and Business Overview
Table 61. HRC Fertility Human Oocyte Cryopreservation Product
Table 62. HRC Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 64. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 65. HRC Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 66. HRC Fertility Recent Developments
Table 67. IVF Australia Corporation Information
Table 68. IVF Australia Description and Business Overview
Table 69. IVF Australia Human Oocyte Cryopreservation Product
Table 70. IVF Australia Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 72. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 73. IVF Australia Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 74. IVF Australia Recent Developments
Table 75. Kindbody Corporation Information
Table 76. Kindbody Description and Business Overview
Table 77. Kindbody Human Oocyte Cryopreservation Product
Table 78. Kindbody Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 80. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 81. Kindbody Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 82. Kindbody Recent Developments
Table 83. London Women’s Clinic Corporation Information
Table 84. London Women’s Clinic Description and Business Overview
Table 85. London Women’s Clinic Human Oocyte Cryopreservation Product
Table 86. London Women’s Clinic Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 88. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 89. London Women’s Clinic Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 90. London Women’s Clinic Recent Developments
Table 91. Manchester Fertility Corporation Information
Table 92. Manchester Fertility Description and Business Overview
Table 93. Manchester Fertility Human Oocyte Cryopreservation Product
Table 94. Manchester Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 96. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 97. Manchester Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 98. Manchester Fertility Recent Developments
Table 99. Mayo Clinic Corporation Information
Table 100. Mayo Clinic Description and Business Overview
Table 101. Mayo Clinic Human Oocyte Cryopreservation Product
Table 102. Mayo Clinic Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 104. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 105. Mayo Clinic Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 106. Mayo Clinic Recent Developments
Table 107. Melbourne IVF Corporation Information
Table 108. Melbourne IVF Description and Business Overview
Table 109. Melbourne IVF Human Oocyte Cryopreservation Product
Table 110. Melbourne IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 112. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 113. Melbourne IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 114. Melbourne IVF Recent Developments
Table 115. Monash IVF Corporation Information
Table 116. Monash IVF Description and Business Overview
Table 117. Monash IVF Human Oocyte Cryopreservation Product
Table 118. Monash IVF Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 120. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 121. Monash IVF Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 122. Monash IVF Recent Developments
Table 123. Pacific Fertility Center-Los Angeles (PFCLA) Corporation Information
Table 124. Pacific Fertility Center-Los Angeles (PFCLA) Description and Business Overview
Table 125. Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Product
Table 126. Pacific Fertility Center-Los Angeles (PFCLA) Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 128. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 129. Pacific Fertility Center-Los Angeles (PFCLA) Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 130. Pacific Fertility Center-Los Angeles (PFCLA) Recent Developments
Table 131. PIVET Corporation Information
Table 132. PIVET Description and Business Overview
Table 133. PIVET Human Oocyte Cryopreservation Product
Table 134. PIVET Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 136. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 137. PIVET Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 138. PIVET Recent Developments
Table 139. Prelude Fertility Corporation Information
Table 140. Prelude Fertility Description and Business Overview
Table 141. Prelude Fertility Human Oocyte Cryopreservation Product
Table 142. Prelude Fertility Human Oocyte Cryopreservation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Product in 2024
Table 144. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Application in 2024
Table 145. Prelude Fertility Revenue Proportion of Human Oocyte Cryopreservation by Geographic Area in 2024
Table 146. Prelude Fertility Recent Developments
Table 147. North America Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 148. North America Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 149. North America Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 150. North America Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 151. Asia-Pacific Human Oocyte Cryopreservation Revenue by Region (2020-2025) & (US$ Million)
Table 152. Asia-Pacific Human Oocyte Cryopreservation Revenue by Region (2026-2031) & (US$ Million)
Table 153. Asia-Pacific Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 154. Asia-Pacific Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 155. Europe Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 156. Europe Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 157. Europe Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 158. Europe Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 159. Latin America Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 160. Latin America Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 161. Latin America Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 162. Latin America Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 163. Middle East and Africa Human Oocyte Cryopreservation Revenue by Country (2020-2025) & (US$ Million)
Table 164. Middle East and Africa Human Oocyte Cryopreservation Revenue by Country (2026-2031) & (US$ Million)
Table 165. Middle East and Africa Human Oocyte Cryopreservation Revenue by Type (2020-2025) & (US$ Million)
Table 166. Middle East and Africa Human Oocyte Cryopreservation Revenue by Application (2020-2025) & (US$ Million)
Table 167. Human Oocyte Cryopreservation Key Raw Materials, Industry Status and Trend
Table 168. Human Oocyte Cryopreservation Key Raw Materials and Upstream Suppliers
Table 169. Human Oocyte Cryopreservation Clients Status and Trend
Table 170. Human Oocyte Cryopreservation Typical Clients
Table 171. Human Oocyte Cryopreservation Distributors
Table 172. Human Oocyte Cryopreservation Market Trends
Table 173. Human Oocyte Cryopreservation Market Drivers
Table 174. Human Oocyte Cryopreservation Market Challenges
Table 175. Human Oocyte Cryopreservation Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Oocyte Cryopreservation Product Picture
Figure 2. Global Human Oocyte Cryopreservation Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Human Oocyte Cryopreservation Revenue Market Share by Type in 2024 & 2031
Figure 4. Slow-cooling Method Product Picture
Figure 5. Flash-freezing Process (Vitrification) Product Picture
Figure 6. Global Human Oocyte Cryopreservation Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Human Oocyte Cryopreservation Revenue Market Share by Application in 2024 & 2031
Figure 8. 25-30 Year Old Female
Figure 9. 30-35 Year Old Female
Figure 10. 35-40 Year Old Female
Figure 11. Others
Figure 12. Human Oocyte Cryopreservation Report Years Considered
Figure 13. Global Human Oocyte Cryopreservation Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Human Oocyte Cryopreservation Market Size (2020-2031) & (US$ Million)
Figure 15. Global Human Oocyte Cryopreservation Market Size Market Share by Region: 2024 Versus 2031
Figure 16. Global Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
Figure 17. Global Human Oocyte Cryopreservation Revenue Market Share Forecast by Type (2020-2031)
Figure 18. Global Human Oocyte Cryopreservation Revenue Market Share Forecast by Application (2020-2031)
Figure 19. Slow-cooling Method of Human Oocyte Cryopreservation Revenue Market Share by Application, 2024 VS 2031
Figure 20. Flash-freezing Process (Vitrification) of Human Oocyte Cryopreservation Revenue Market Share by Application, 2024 VS 2031
Figure 21. Human Oocyte Cryopreservation Revenue Share by Company (2024)
Figure 22. Human Oocyte Cryopreservation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Slow-cooling Method Revenue Proportion by Company in 2024
Figure 24. Flash-freezing Process (Vitrification) Revenue Proportion by Company in 2024
Figure 25. North America Human Oocyte Cryopreservation Revenue 2020-2031 (US$ Million)
Figure 26. North America Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 27. North America Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 28. Asia-Pacific Human Oocyte Cryopreservation Revenue 2020-2031 (US$ Million)
Figure 29. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Region (2020-2031)
Figure 30. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 31. Asia-Pacific Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 32. Europe Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 33. Europe Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 34. Europe Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 35. Europe Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 36. Latin America Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 37. Latin America Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 38. Latin America Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 39. Latin America Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 40. Middle East and Africa Human Oocyte Cryopreservation Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Country (2020-2031)
Figure 42. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Type (2020-2025)
Figure 43. Middle East and Africa Human Oocyte Cryopreservation Revenue Market Share by Application (2020-2025)
Figure 44. Human Oocyte Cryopreservation Supply Chain (Upstream and Downstream Market)
Figure 45. Global Production Market Share of Human Oocyte Cryopreservation Raw Materials by Region in 2024
Figure 46. Human Oocyte Cryopreservation Distribution Channels
Figure 47. Global Human Oocyte Cryopreservation Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 48. Global Human Oocyte Cryopreservation Percentage 2020-2031: Online Sales VS Offline Sales
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232